August 14, 2020

Volume X, Number 227

August 13, 2020

Subscribe to Latest Legal News and Analysis

August 12, 2020

Subscribe to Latest Legal News and Analysis

August 11, 2020

Subscribe to Latest Legal News and Analysis

Gilead Facing Multiple Claims of Purposefully Delaying Safer HIV Drug Alternatives

It has been alleged that Gilead Sciences, an HIV drugmaker, purposefully delayed the introduction of safer, life-saving medications in order to increase profits.

In 2001, Gilead received approval for the sale of HIV drugs containing the compound, tenofovir disoproxil fumarate (TDF). Unfortunately, TDF medications have been linked to severe kidney and bone injuries. However, numerous lawsuits, including one filed by the AIDS Healthcare Foundation, have alleged that Gilead had, in fact, developed a much safer HIV treatment compound, tenofovir alafemanide fumarate (TAF).

It is further alleged that Gilead purposefully delayed the introduction of the safer TAF drugs, despite Gilead’s knowledge of the injuries being caused by the TDF drugs, in order to reap extended profits from Gilead’s drug patents on the TDF drugs (at the height of usage, Gilead’s TDF drugs were earning over $10 billion in annual sales). This has allegedly resulted in tens of thousands of reports of severe injuries.

If you are an HIV patient that was treated with Atripla, Complera, Stribild, Truvada, or Viread, you may be wrongly suffering from kidney injuries (including acute kidney injury, chronic kidney disease, renal failure, or related injuries), or bone injuries (including fractures, osteoporosis, osteopenia or related injuries).

COPYRIGHT © 2020, STARK & STARKNational Law Review, Volume VIII, Number 177


About this Author

Martin P. Schrama, Stark Law, Intellectual Property and Litigation Law Attorney

Martin P. Schrama is a Shareholder in Stark & Stark's Commercial Litigation, Mass Tort, Intellectual Property and Green Litigation Groups. Mr. Schrama has extensive experience litigating on both the trial and appellate levels of the federal and state courts of New Jersey and New York, as well as numerous other jurisdictions throughout the nation in a pro hac vice capacity. This experience also extends to regular practice before AAA, JAMS and various other alternate dispute resolution fora.

The primary focus of Mr. Schrama’s practice is...

Stefanie Colella Walsh, Pharmaceutical Litigation Attorney, Stark Law Firm

Stefanie Colella-Walsh is a Shareholder and member of Stark & Stark’s Litigation, Insurance Coverage & Liability, Intellectual Property and Mass Torts Groups where she concentrates her practice in complex litigation with a focus in mass tort and pharmaceutical litigation. She also handles litigation related to nursing home negligence and abuse claims, elder abuse, and assisted living facility litigation.

Recently, Ms. Colella-Walsh was a member of the national trial team involved the first trial in the country of a TVT-Secur transvaginal mesh device case against Ethicon/Johnson and Johnson.